secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2022-02-08T23:59:59+00:00
Accession:  0001558370-22-000883
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q4 product/royalty rev $813M (+20%); non-GAAP EPS $0.10; 2022 Jakafi guidance $2.3-2.4B
--------------------------------------------------------------------------------

- Jakafi net product revenues $592M in Q4 (+15%) and $2.135B for FY21 (+10%).
- GAAP net income $563.9M includes $569M tax benefit from valuation allowance release; non-GAAP diluted EPS $0.10.
- Opzelura launch: ~19,000 patients treated in Q4; vitiligo sNDA under Priority Review with PDUFA April 18, 2022.
- Parsaclisib NDA withdrawn for FL/MZL/MCL in U.S.; baricitinib SLE Phase 3 discontinued; baricitinib AD sNDA faces potential CRL.
- 2022 guidance: Jakafi $2.3-2.4B, other heme/onc $210-240M; GAAP R&D $1.55-1.59B, SG&A $950M-1B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000155837022000883/0001558370-22-000883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000155837022000883/incy-20220208x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-000883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer